Kristin Leonardi-Warren, RN, ND; Mary S. McCabe, RN, BS, MS; Michelle Melisko, MD; Jose G. Montoya, MD; Kathi Mooney, RN, PhD; Mary Ann Morgan, PhD, FNP-BC; Javid J. Moslehi, MD; Tracey O’Connor, MD; Linda Overholser, MD, MPH; Electra D. Paskett, PhD; Jeffrey Peppercorn, MD, MPH; Muhammad Raza, MD; M. Alma Rodriguez, MD; Karen L. Syrjala, PhD; Susan G. Urba, MD; Mark T. Wakabayashi, MD, MPH; Phyllis Zee, MD; Nicole R. McMillian, MS; and Deborah A. Freedman-Cass, PhD

Screening for Effects of Cancer and Its Treatment

All survivors should be periodically screened for symptoms related to cancer and previous cancer treatment, with appropriate follow-up care as clinically indicated. The panel does not assume that all survivorship issues will be addressed at every visit. Some tools that screen...
for long-term and late physical and psychosocial effects of cancer and its treatment in survivors have been validated. In addition, the NCCN Survivorship Panel created a sample screening instrument that is guideline-specific and can be self-administered or administered by an interviewer. This assessment tool was developed specifically for use in combination with the NCCN Clinical Practice Guidelines in Oncology for Survivorship to help providers deliver necessary and comprehensive survivorship care (to view the most recent and complete version of these guidelines, visit NCCN.org). Although this instrument has not yet been piloted or validated, the answers can be used to guide providers to topics within the guidelines that require more in-depth assessment via validated tools and/or clinical evaluation.

In addition to screening by history and physical examination, care providers should assess the following to determine whether reversible or contributing causes exist:

- Current disease status
- Functional/performance status
- Current medications
- Comorbidities, including weight and tobacco use
- Prior cancer treatment history and modalities used

This information can also inform about the patient’s risk for specific late or long-term effects, including risks for second primary cancers and comorbidities. For example, patients who received pelvic irradiation or surgery are at risk for sexual dysfunction; patients with a history of brain metastasis or cranial irradiation have an elevated risk for cognitive effects of cancer and its treatment in survivors have not been validated.

KEY:

- Writing Committee Member
- Subcommittees: Anxiety and Depression; Cognitive Function; Exercise; Fatigue; Immunizations and Infections; Pain; Sexual Function; Sleep Disorders
- Specialties: Bone Marrow Transplantation; Cardiology; Epidemiology; Exercise/Physiology; Gynecology; Gynecologic Oncology; Hematology; Hematology Oncology; Infectious Diseases; Pinternal Medicine; Medical Oncology; Neurology; Neuro-Oncology; Nursing; Nutrition Science; Dietician; Patient Advocacy; Pediatric Oncology; Psychiatry; Psychology, Including Health Behavior; Supportive Care; Palliative, Pain Management, Pastoral Care, and Oncology Social Work; Surgery/Surgical Oncology; Urology

NCCN Survivorship Panel Members

include:

- Crystal S. Denlinger, MD/Chair
- Jennifer A. Ligibel, MD/Vice Chair
- Madhuri Are, MD
- Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center
- Scott Baker, MD, MSE
- Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
- Wendy Demark-Wahnefried, PhD, RD
- University of Alabama at Birmingham Comprehensive Cancer Center
- Don Dixon
- Massachusetts General Hospital Cancer Center
- Debra L. Friedman, MD, MS
- Vanderbilt Ingram Cancer Center
- Mindy Goldman, MD
- UCSF Helen Diller Family Comprehensive Cancer Center
- Lee Jones, PhD
- Memorial Sloan Kettering Cancer Center
- Allison King, MD
- Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
- Grace H. Ku, MD
- UC San Diego Moores Cancer Center
- Elizabeth Kvale, MD
- University of Alabama at Birmingham Comprehensive Cancer Center
- Terry S. Langbaum, MASY
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Kristin Leonardi-Warren, RN, ND
- University of Colorado Cancer Center
- Mary S. McCabe, RN, BS, MS
- Memorial Sloan Kettering Cancer Center
- Michelle Melisko, MD
- UCSF Helen Diller Family Comprehensive Cancer Center
- Jose G. Montoya, MD
- Stanford Cancer Institute
- Kathi Mooney, RN, PhD
- Huntsman Cancer Institute at the University of Utah
- Mary Ann Morgan, PhD, FNP-BC
- Moffitt Cancer Center

Javid J. Moslehi, MD
- Vanderbilt Ingram Cancer Center
- Tracey O’Connor, MD
- Roswell Park Cancer Institute
- Linda Overholser, MD, MPH
- University of Colorado Cancer Center
- Electra D. Paskett, PhD
- The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
- Jeffrey Peppercorn, MD, MPH
- Duke Cancer Institute
- Muhammad Raza, MD
- St. Jude Children’s Research Hospital
- The University of Tennessee Health Science Center
- M. Alma Rodriguez, MD
- The University of Texas MD Anderson Cancer Center
- Karen L. Syrjala, PhD
- Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
- Susan G. Urba, MD
- University of Michigan Comprehensive Cancer Center
- Mark T. Wakabayashi, MD, MPH
- City of Hope Comprehensive Cancer Center
- Phyllis Zee, MD
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University

NCCN Staff: Nicole R. McMillian, MS, and Deborah A. Freedman-Cass, PhD

© JNCCN—Journal of the National Comprehensive Cancer Network | Volume 12 Number 11 | November 2014
SURVIVORSHIP BASELINE ASSESSMENT
(Patient version)

Please answer the following questions regarding possible symptoms that you may have experienced over the past 4 weeks:

<table>
<thead>
<tr>
<th>Survivorship Concerns</th>
<th>Survivorship Care Survey</th>
</tr>
</thead>
</table>
| Anxiety and Depression       | 1. Do you often feel nervous or do you worry? Yes/No  
2. Do you often feel sad or depressed? Yes/No  
3. Have you lost interest in things you used to enjoy? Yes/No |
| Cognitive Function            | 4. Do you have difficulties with multitasking or attention? Yes/No  
5. Do you have difficulties with remembering things? Yes/No  
6. Does your thinking seem slow? Yes/No |
| Fatigue                       | 7. Do you feel persistent fatigue despite a good night's sleep? Yes/No  
8. Does fatigue interfere with your usual activities? Yes/No  
9. How would you rate your fatigue on a scale of 0 (none) to 10 (extreme) over the past month? 0-10 |
| Pain                          | 10. Are you having any pain? Yes/No  
11. How would you rate your pain on a scale of 0 (none) to 10 (extreme) over the past month? 0-10 |
| Sexual Function               | 12. Are you dissatisfied with your sexual function? Yes/No  
13. Do you have any concerns regarding sexual function or sexual activity? Yes/No |
| Sleep Disorder                | 14. Are you having problems falling asleep or staying asleep? Yes/No  
15. Are you experiencing excessive sleepiness (ie, sleepiness or falling asleep in inappropriate situations or sleeping more during a 24-hour period than in the past)? Yes/No |
| Physical Activity             | 16. Are you exercising or doing some physical activity for less than 150 minutes a week? Yes/No  
17. Do you have any limitations to participating in the physical activities that you enjoy? Yes/No |
| Immunizations and Infections  | 18. Have you received your flu vaccine this year? Yes/No  
19. Have you received any vaccinations recently? Yes/No |

SURV-A 1 of 2
**SURVIVORSHIP BASELINE ASSESSMENT**
(Provider Key)

Please answer the following questions regarding possible symptoms that you may have experienced over the past 4 weeks:

<table>
<thead>
<tr>
<th>Survivorship Concerns</th>
<th>Survivorship Care Survey</th>
<th>Provider Key</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anxiety and Depression</td>
<td>Questions 1-3</td>
<td>If YES to any question, refer to SANXDE-1*</td>
</tr>
<tr>
<td>Cognitive Function</td>
<td>Questions 4-6</td>
<td>If YES to any question, refer to SCF-1*</td>
</tr>
<tr>
<td>Fatigue</td>
<td>Questions 7-9</td>
<td>If YES to either question 7 or 8, or a rating of &gt;3 to question 9, refer to SFAT-1*</td>
</tr>
<tr>
<td>Pain</td>
<td>Questions 10-11</td>
<td>If YES to question 10 and a rating of &gt;4 to question 11, refer to SPAIN-1*</td>
</tr>
<tr>
<td>Sexual Function</td>
<td>Questions 12-13</td>
<td>If YES to either question, refer to SSFF-1* (female) or SSFM-1* (male)</td>
</tr>
<tr>
<td>Sleep Disorder</td>
<td>Questions 14-15</td>
<td>If YES to either question, refer to SSD-1*</td>
</tr>
<tr>
<td>Physical Activity</td>
<td>Questions 16-17</td>
<td>If YES to either question, refer to HL-1*</td>
</tr>
<tr>
<td>Immunizations and Infections</td>
<td>Questions 18-19</td>
<td>If NO to either question, refer to SIMIN-1*</td>
</tr>
</tbody>
</table>

*Available online, in these guidelines, at NCCN.org.

*This is a sample assessment tool. While this instrument has not yet been piloted or validated, the answers can be used to guide providers to topics within the guidelines that require more in-depth assessment. Validation of the best way to assess survivorship issues is ongoing.
tive dysfunction. In general, those who underwent more intensive therapy are at higher risk for multiple late and/or long-term effects. Survivors undergoing certain treatments, such as mantle radiation or certain systemic therapy agents, may be at increased risk for secondary malignancies. Survivors who continue to smoke are at increased risk for smoking-related co-morbidities and second primary cancers.

References


### Individual Disclosures for the NCCN Survivorship Panel

<table>
<thead>
<tr>
<th>Panel Member</th>
<th>Clinical Research Support/Data Safety Monitoring Board</th>
<th>Advisory Boards, Speakers Bureau, Expert Witness, or Consultant</th>
<th>Patent, Equity, or Royalty</th>
<th>Other</th>
<th>Date Completed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Madhuri Are, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>9/6/14</td>
</tr>
<tr>
<td>K. Scott Baker, MD, MS</td>
<td>Cincinnati Children’s Medical Center</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>10/21/14</td>
</tr>
<tr>
<td>Wendy Demark-Wahnefried, PhD, RD</td>
<td>National Cancer Institute; American Cancer Society; Harvest for Health Gardening Project for Breast Cancer Survivors; and Nutrigenomic Link between Alpha-Linolenic Acid and Aggressive Prostate Cancer</td>
<td>American Society of Clinical Oncology</td>
<td>None</td>
<td>American Society of Preventive Oncology</td>
<td>7/13/14</td>
</tr>
<tr>
<td>Crystal S. Denlinger, MD</td>
<td>Bayer HealthCare; Genentech, Inc.; ImClone Systems Incorporated; MedImmune Inc.; OncoMed Pharmaceuticals; Astex Pharmaceuticals; Merrimack Pharmaceuticals; and Pfizer Inc.</td>
<td>Eli Lilly and Company</td>
<td>None</td>
<td>None</td>
<td>10/16/14</td>
</tr>
<tr>
<td>Don Dizon, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>4/4/14</td>
</tr>
<tr>
<td>Debra L. Friedman, MD, MS</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>7/31/14</td>
</tr>
<tr>
<td>Mindy Goldman, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Lumetra</td>
<td>8/23/14</td>
</tr>
<tr>
<td>Lee W. Jones, PhD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>8/2/14</td>
</tr>
<tr>
<td>Allison King, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>9/11/13</td>
</tr>
<tr>
<td>Grace H. Ku, MD</td>
<td>None</td>
<td>Seattle Genetics, Inc.</td>
<td>None</td>
<td>None</td>
<td>9/16/14</td>
</tr>
<tr>
<td>Elizabeth Kvale, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>10/23/14</td>
</tr>
<tr>
<td>Terry S. Langbaum, MAS</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>8/22/14</td>
</tr>
<tr>
<td>Kristin Leonardi-Warren, RN, ND</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>1/6/14</td>
</tr>
<tr>
<td>Jennifer A. Ligibel, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>10/3/13</td>
</tr>
<tr>
<td>Mary S. McCabe, RN, BS, MS</td>
<td>None</td>
<td>National Cancer Institute</td>
<td>None</td>
<td>None</td>
<td>5/6/14</td>
</tr>
<tr>
<td>Michelle Melisko, MD</td>
<td>Genentech, Inc.; Cell therapeutics; and Galena Biopharma</td>
<td>Agendia BV</td>
<td>None</td>
<td>None</td>
<td>8/19/14</td>
</tr>
<tr>
<td>Jose G. Montoya, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>12/6/13</td>
</tr>
<tr>
<td>Kathii Mooney, RN, PhD, PNP-BC</td>
<td>None</td>
<td>University of Utah</td>
<td>None</td>
<td>None</td>
<td>7/15/14</td>
</tr>
<tr>
<td>Mary Ann Morgan, PhD, PNP-BC</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>5/5/14</td>
</tr>
<tr>
<td>Javid J. Mosleh, MD</td>
<td>Millennium Pharmaceuticals, Inc.; and Acleron, Inc.</td>
<td>ARIAD Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer Inc.</td>
<td>None</td>
<td>None</td>
<td>10/5/14</td>
</tr>
<tr>
<td>Tracey O’Connor, MD</td>
<td>None</td>
<td>Colorado Central Cancer Registry Care Plan Project; and George Washington Cancer Institute Survivorship Project</td>
<td>None</td>
<td>Athena Health</td>
<td>10/13/14</td>
</tr>
<tr>
<td>Linda Overholser, MD, MPH</td>
<td>None</td>
<td>None</td>
<td>Athena Health</td>
<td>None</td>
<td>9/24/14</td>
</tr>
<tr>
<td>Electra D. Paskett, PhD, PhD</td>
<td>Merck &amp; Co., Inc.</td>
<td>None</td>
<td>Pfizer Inc.</td>
<td>None</td>
<td>9/2/14</td>
</tr>
<tr>
<td>Jeffrey Peppercorn, MD, MPH</td>
<td>None</td>
<td>Genentech, Inc.</td>
<td>GlaxoSmithKline</td>
<td>None</td>
<td>8/2/14</td>
</tr>
<tr>
<td>Muhammad Raza, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>8/23/12</td>
</tr>
<tr>
<td>M. Alma Rodriguez, MD</td>
<td>Amgen Inc.; and Ortho Biotech Products, L.P.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>9/16/14</td>
</tr>
<tr>
<td>Karen L. Syrjala, PhD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>9/2/14</td>
</tr>
<tr>
<td>Susan G. Urba, MD</td>
<td>None</td>
<td>Eisai Inc.</td>
<td>None</td>
<td>None</td>
<td>8/21/14</td>
</tr>
<tr>
<td>Mark T. Wakabayashi, MD, MPH</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>9/5/14</td>
</tr>
<tr>
<td>Phyllis Zee, MD</td>
<td>Philips/Respironics</td>
<td>None</td>
<td>Merck &amp; Co., Inc.; Jazz Pharmaceuticals; Vanda Pharmaceuticals; and Aptalis Pharmaceuticals</td>
<td>None</td>
<td>8/28/14</td>
</tr>
</tbody>
</table>

The NCCN Guidelines Staff have no conflicts to disclose.